Methods of treating cancer using bacteria expressing c-di-AMP

US11590177B2 · kind B2 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• William R. Bishai · Baltimore, US
• Ruchi Jain Dey · Baltimore, US
• Bappaditya Dey · Baltimore, US
• Laurene Cheung · Baltimore, US

Key dates

• Filing date: Nov 19, 2020
• Grant date: Feb 28, 2023
• Expiry date: Nov 19, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/522
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.